Developer docs
API playgroundTry for free, no card

Search company profiles

ZIG Ventures

Full company profile

uuid000b9w2

Namestring
ZIG Ventures
Legal namestring
ZIG Ventures Limited
Websiteurl
ziggroup.com.sg
Company typeenum
Private
Founded yearint
2014
Descriptiontext

ZIG Ventures is a Singapore-based venture investment and commercialization company focused on early-stage healthcare and biomedical technology companies across the Asia Pacific region. Founded in 2014 as the corporate venturing arm of Zicom Group and demerged in 2018 to operate independently, the firm identifies early-stage medtech innovations in oncology, ophthalmology, healthcare analytics, and life sciences, and actively develops them by working side-by-side with founders to build capabilities and drive commercialization. Its disclosed portfolio of five companies—Biobot Surgical, Histoindex, Curiox Biosystems, Pellucid, Endofotonics, and BELKIN Laser—spans robotic surgery, bioinstrumentation, AI-assisted cancer detection, and ophthalmic devices.

ZIG's business model combines equity investment with an operational commercialization layer. The wholly-owned subsidiary ZIG MedTech Asia provides Asia Pacific market entry services, including product registration, market penetration, and distributorship management, while ZIG itself acts as the global distributor for products such as Biobot Surgical's iSR'obot Mona Lisa robotic biopsy system. The firm is a co-investment partner of SEEDS Capital under Singapore's Startup SG Equity scheme and since March 2021 has been a partner under the Enterprise Singapore Innovation and Enterprise Fellowship (IFP) Programme, which feeds its ZIG Innovation Fellowship talent pipeline. Capital deployment is led by Chairman Sim Giok Lak and CEO Sim Kok Hwee, with the firm holding board representation across key portfolio companies.

ZIG's revenue mechanics are typical of a venture platform: returns are generated through equity stakes in early-stage medtech companies, with realizations occurring via IPOs, follow-on rounds, and acquisitions. The August 2023 KOSDAQ IPO of cornerstone portfolio company Curiox Biosystems (1,400,000 shares at 13,000 won per share) is a recent successful exit, while ongoing rounds such as the $7.85M Biobot Surgical financing led by ZIG (2026) and the $12.25M BELKIN Laser Series B (2020) reflect continued capital deployment. The firm does not disclose AUM, management fees, carry, or firm-level revenue.

Short descriptiontext

ZIG Ventures is a Singapore-based venture investment and commercialization company that backs early-stage medtech companies across Asia Pacific, providing capital, operational support, and APAC market entry through its ZIG MedTech Asia subsidiary and global distribution relationships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, healthcare commercialization, medtech investments, life sciences venture, medical device distribution
Industry4 codes
PRIMARYFSANAHAC
Corporate Venture Studios & Incubators (Build/launch ventures)
SECONDARYFSANAHAI
Corporate Innovation & Technology Scouting Units (with investment mandate)
SECONDARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms
SECONDARYBPAHACAA
Strategy & Corporate Development Consulting
NAICS code1 code
  • Management Consulting Services54161
SIC code1 code
  • Services-Management Consulting Services8742
Product category
Venture Capital / Healthcare Commercialization Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Returns
TypeSubscription Recurring
Description

ZIG Ventures generates returns through equity investments in early-stage healthcare medtech companies, providing capital in exchange for ownership stakes. Returns are realized through IPO exits, follow-on funding rounds, and acquisitions of portfolio companies.

ziggroup.com.sg
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ZIG Ventures is a venture investment and commercialization company that invests in early-stage healthcare biomedical technology companies in the Asia Pacific region. It works alongside founders to build capabilities and drive commercialization through its dedicated commercialization arm, ZIG MedTech Asia, which supports product registration, market penetration, and distributorship management across Asia Pacific. The firm also acts as the appointed global distributor for select portfolio products such as Biobot Surgical's iSR'obot Mona Lisa.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Successful IPO exit of Curiox Biosystems on KOSDAQ in August 2023
+2 more records
Product overview1 text field

ZIG Ventures is a venture investment and commercialization platform focusing on healthcare innovations in the Asia Pacific region. The company invests in healthcare biomedical technology companies and actively develops them by working with founders, building capabilities, and driving commercialization. ZIG MedTech Asia serves as the commercialization arm supporting product registration, market penetration, and distributorship management in the Asia Pacific region. The portfolio includes: Biobot Surgical's iSR'obot™ Mona Lisa robotic biopsy system; Curiox Biosystems' Laminar Wash™ product line (HT1000, AUTO 1000, and MINI) for automated sample preparation; Endofotonics' SPECTRA IMDx™ AI-powered Raman spectroscopy system for early gastric cancer detection; BELKIN Laser's one-second glaucoma laser treatment device; and portfolio companies Histoindex and Pellucid.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1ZIG MedTech Asia
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

ZIG MedTech Asia is the commercialization arm of ZIG Ventures established to work closely with portfolio companies to support product registration, market penetration, and distributorship management activities in the Asia Pacific region.

ziggroup.com.sg
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct co-investment partner of ZIG Ventures under the Startup SG Equity scheme. SEEDS Capital is a wholly-owned entity of Enterprise Singapore that co-invests in Singapore-based early-stage startups, sharing deal-flow, governance frameworks, and government backing.

TypeOthers
Description

Former parent of ZIG Ventures prior to the 2018 demerger. Zicom is a diversified engineering and manufacturing business, providing context on ZIG's origins as a corporate venturing arm and potential ecosystem overlap.

TypeBroad incumbent
Description

Denmark-based holding company of the Novo Nordisk Foundation with significant healthcare and life-sciences venture investing arm. Comparable as a mission-driven, healthcare-focused investor with long-duration capital, though at much greater scale.

TypeBroad incumbent
Description

Asia's largest healthcare-dedicated investment firm spanning venture, growth, and buyout across the region. Comparable in healthcare-only mandate but operates at materially larger scale and AUM.

TypeBroad incumbent
Description

Global healthcare-dedicated investment firm across venture, growth, and public equity. Comparable in healthcare-only thematic focus but with significantly broader geographic footprint and larger fund vehicles.

TypeBroad incumbent
Description

Healthcare-focused investment manager operating across public and private markets. Comparable in healthcare-only thesis and crossover investing into clinical-stage assets, though at materially larger scale.

TypeBroad incumbent
Description

US-based early-stage venture firm specializing in life sciences, physical sciences and cleantech. Comparable in deep-tech/healthcare focus and willingness to incubate companies from research institutions, though much larger AUM.

TypeOthers
Description

Singapore government agency that operates SEEDS Capital and the IFP program through which ZIG accesses co-investment capital and talent. Functioning as an LP/co-investor ecosystem enabler rather than a direct competitor.

TypeDirect peer
Description

Singapore government-linked deep-tech investor that funds and builds science-based startups, particularly in healthcare and biomedical sciences. Comparable as a Singapore-anchored deep-tech commercialization platform.

10Heritas Capital
TypeDirect peer
Description

Singapore-based venture and growth investor focused on healthcare and deep-tech, with similar mandate of backing early-stage health and life-sciences innovators across Asia. Directly comparable in sector focus and stage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment7 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ZIG Ventures

Venture Capital / Healthcare Commercialization Servicesziggroup.com.sg

ZIG Ventures is a Singapore-based venture investment and commercialization company that backs early-stage medtech companies across Asia Pacific, providing capital, operational support, and APAC market entry through its ZIG MedTech Asia subsidiary and global distribution relationships.

What ZIG Ventures does

ZIG Ventures is a Singapore-based venture investment and commercialization company focused on early-stage healthcare and biomedical technology companies across the Asia Pacific region. Founded in 2014 as the corporate venturing arm of Zicom Group and demerged in 2018 to operate independently, the firm identifies early-stage medtech innovations in oncology, ophthalmology, healthcare analytics, and life sciences, and actively develops them by working side-by-side with founders to build capabilities and drive commercialization. Its disclosed portfolio of five companies—Biobot Surgical, Histoindex, Curiox Biosystems, Pellucid, Endofotonics, and BELKIN Laser—spans robotic surgery, bioinstrumentation, AI-assisted cancer detection, and ophthalmic devices.

ZIG's business model combines equity investment with an operational commercialization layer. The wholly-owned subsidiary ZIG MedTech Asia provides Asia Pacific market entry services, including product registration, market penetration, and distributorship management, while ZIG itself acts as the global distributor for products such as Biobot Surgical's iSR'obot Mona Lisa robotic biopsy system. The firm is a co-investment partner of SEEDS Capital under Singapore's Startup SG Equity scheme and since March 2021 has been a partner under the Enterprise Singapore Innovation and Enterprise Fellowship (IFP) Programme, which feeds its ZIG Innovation Fellowship talent pipeline. Capital deployment is led by Chairman Sim Giok Lak and CEO Sim Kok Hwee, with the firm holding board representation across key portfolio companies.

ZIG's revenue mechanics are typical of a venture platform: returns are generated through equity stakes in early-stage medtech companies, with realizations occurring via IPOs, follow-on rounds, and acquisitions. The August 2023 KOSDAQ IPO of cornerstone portfolio company Curiox Biosystems (1,400,000 shares at 13,000 won per share) is a recent successful exit, while ongoing rounds such as the $7.85M Biobot Surgical financing led by ZIG (2026) and the $12.25M BELKIN Laser Series B (2020) reflect continued capital deployment. The firm does not disclose AUM, management fees, carry, or firm-level revenue.

ZIG Ventures firmographics

Firmographics
Name
ZIG Ventures
Legal name
ZIG Ventures Limited
Website
https://ziggroup.com.sg
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
ZIG Ventures is a Singapore-based venture investment and commercialization company that backs early-stage medtech companies across Asia Pacific, providing capital, operational support, and APAC market entry through its ZIG MedTech Asia subsidiary and global distribution relationships.
Ownership category
akta.pro rank

ZIG Ventures industry classification

Industry
Product category
Venture Capital / Healthcare Commercialization Services
NAICS
Management Consulting Services (54161)
SIC
Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYFSANAHAC
Corporate Venture Studios & Incubators (Build/launch ventures)
SECONDARYFSANAHAI
Corporate Innovation & Technology Scouting Units (with investment mandate)
SECONDARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms
SECONDARYBPAHACAA
Strategy & Corporate Development Consulting

Keywords

  • Venture capital investing
  • Healthcare commercialization
  • Medtech investments
  • Life sciences venture
  • Medical device distribution

Where ZIG Ventures is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices1 record

Markets served

ZIG Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Venture Capital Returns: ZIG Ventures generates returns through equity investments in early-stage healthcare medtech companies, providing capital in exchange for ownership stakes. Returns are realized through IPO exits, follow-on funding rounds, and acquisitions of portfolio companies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

ZIG Ventures product offering

Product offering

Core offering

ZIG Ventures is a venture investment and commercialization company that invests in early-stage healthcare biomedical technology companies in the Asia Pacific region. It works alongside founders to build capabilities and drive commercialization through its dedicated commercialization arm, ZIG MedTech Asia, which supports product registration, market penetration, and distributorship management across Asia Pacific. The firm also acts as the appointed global distributor for select portfolio products such as Biobot Surgical's iSR'obot Mona Lisa.

Product overview

ZIG Ventures is a venture investment and commercialization platform focusing on healthcare innovations in the Asia Pacific region. The company invests in healthcare biomedical technology companies and actively develops them by working with founders, building capabilities, and driving commercialization. ZIG MedTech Asia serves as the commercialization arm supporting product registration, market penetration, and distributorship management in the Asia Pacific region. The portfolio includes: Biobot Surgical's iSR'obot™ Mona Lisa robotic biopsy system; Curiox Biosystems' Laminar Wash™ product line (HT1000, AUTO 1000, and MINI) for automated sample preparation; Endofotonics' SPECTRA IMDx™ AI-powered Raman spectroscopy system for early gastric cancer detection; BELKIN Laser's one-second glaucoma laser treatment device; and portfolio companies Histoindex and Pellucid.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Successful IPO exit of Curiox Biosystems on KOSDAQ in August 2023
  • +2 more outcomes

Companies that use ZIG Ventures

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

ZIG Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

ZIG Ventures partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ZIG MedTech AsiacoreStrategic or Co-development Partner · 1 January 2018ZIG MedTech Asia is the commercialization arm of ZIG Ventures established to work closely with portfolio companies to support product registration, market penetration, and distributorship management activities in the Asia Pacific region.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

ZIG Ventures competitors and assessment

Company assessment

Direct peers

  • SEEDS Capital: Direct co-investment partner of ZIG Ventures under the Startup SG Equity scheme. SEEDS Capital is a wholly-owned entity of Enterprise Singapore that co-invests in Singapore-based early-stage startups, sharing deal-flow, governance frameworks, and government backing.
  • SGInnovate: Singapore government-linked deep-tech investor that funds and builds science-based startups, particularly in healthcare and biomedical sciences. Comparable as a Singapore-anchored deep-tech commercialization platform.
  • Heritas Capital: Singapore-based venture and growth investor focused on healthcare and deep-tech, with similar mandate of backing early-stage health and life-sciences innovators across Asia. Directly comparable in sector focus and stage.

Others

  • Zicom Group: Former parent of ZIG Ventures prior to the 2018 demerger. Zicom is a diversified engineering and manufacturing business, providing context on ZIG's origins as a corporate venturing arm and potential ecosystem overlap.
  • Enterprise Singapore: Singapore government agency that operates SEEDS Capital and the IFP program through which ZIG accesses co-investment capital and talent. Functioning as an LP/co-investor ecosystem enabler rather than a direct competitor.

Broad incumbents

  • Novo Holdings: Denmark-based holding company of the Novo Nordisk Foundation with significant healthcare and life-sciences venture investing arm. Comparable as a mission-driven, healthcare-focused investor with long-duration capital, though at much greater scale.
  • CBC Group: Asia's largest healthcare-dedicated investment firm spanning venture, growth, and buyout across the region. Comparable in healthcare-only mandate but operates at materially larger scale and AUM.
  • OrbiMed Advisors: Global healthcare-dedicated investment firm across venture, growth, and public equity. Comparable in healthcare-only thematic focus but with significantly broader geographic footprint and larger fund vehicles.
  • RA Capital Management: Healthcare-focused investment manager operating across public and private markets. Comparable in healthcare-only thesis and crossover investing into clinical-stage assets, though at materially larger scale.
  • ARCH Venture Partners: US-based early-stage venture firm specializing in life sciences, physical sciences and cleantech. Comparable in deep-tech/healthcare focus and willingness to incubate companies from research institutions, though much larger AUM.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

ZIG Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ZIG Ventures leadership team

Management profile

Number of profiles

Profiles2 records

ZIG Ventures subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ZIG Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ZIG Ventures M&A and investment

M&A and investment

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZIG Ventures

What does ZIG Ventures do?

ZIG Ventures is a venture investment and commercialization company that invests in early-stage healthcare biomedical technology companies in the Asia Pacific region. It works alongside founders to build capabilities and drive commercialization through its dedicated commercialization arm, ZIG MedTech Asia, which supports product registration, market penetration, and distributorship management across Asia Pacific. The firm also acts as the appointed global distributor for select portfolio products such as Biobot Surgical's iSR'obot Mona Lisa.

Is ZIG Ventures a public or private company?

ZIG Ventures is a private company. It is classified as management employee owned and is currently operating.

When was ZIG Ventures founded?

ZIG Ventures was founded in 2014. It employs 1 to 10 people.

Where is ZIG Ventures based?

ZIG Ventures is headquartered in Singapore, Singapore, in the Asia region.

How does ZIG Ventures make money?

One revenue line is on record: venture Capital Returns.

Who are ZIG Ventures's main competitors?

Direct peers on record are SEEDS Capital, SGInnovate and Heritas Capital. Others are Zicom Group and Enterprise Singapore. Broad incumbents are Novo Holdings, CBC Group, OrbiMed Advisors, RA Capital Management and ARCH Venture Partners.

Does ZIG Ventures have an API?

No public API is recorded for ZIG Ventures.

What industry is ZIG Ventures in?

ZIG Ventures's product category is Venture Capital / Healthcare Commercialization Services. Its primary akta.pro industry code is FSANAHAC, Corporate Venture Studios & Incubators (Build/launch ventures), with a secondary code of FSANAHAI, Corporate Innovation & Technology Scouting Units (with investment mandate). Its NAICS code is 54161 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
IncubeesBiobot Surgical secures $15 M to bring Robotic Prostate Cancer platform to the U.S. – IncubeesBiobot Surgical, a Singapore-based medical technology startup, raised S$20 million (approximately $15.4 million) in a funding round led by ClavystBio with participation from ZIG Ventures. The funding will accelerate deployment of the company's Mona Lisa platform—which combines robotic needle guiding with MRI-ultrasound image fusion for targeted prostate biopsy and ablation—in foreign markets, particularly the United States. As part of its U.S. commercialization strategy, Biobot has partnered with Fogarty Innovation to identify priority clinical markets and accelerate technology adoption among healthcare providers.TNGlobalSingapore's Biobot Surgical raises $15M to expand robotic prostate cancer platform into US marketBiobot Surgical raised S$20 million ($15.4 million) led by ClavystBio and ZIG Ventures to expand its robotic prostate cancer platform into the US market. The funding will accelerate adoption of its Mona Lisa system, which has deployed over 80 systems globally and supported more than 30,000 patients.Tech in AsiaSingapore medtech firm Biobot raises $15.4m for US pushBiobot Surgical raised S$20 million (US$15.4 million) in a round led by ClavystBio and ZIG Ventures. The funding will support US commercialization of its Mona Lisa prostate cancer platform, which has over 80 systems deployed globally. The company will partner with Fogarty Innovation for US commercialization.SbrStartup exits slow to two acquisitions, one IPO in April to MaySingapore startup exits slowed significantly between April and May 2026, with only two acquisitions and one IPO recorded, compared to 11 acquisitions and three IPOs in the first quarter of 2026. Late-stage funding dominated the period at $157.8m, with Silicon Box's $150m round backed by EDBI as the largest deal, followed by Simple Chain's $15m investment and Biobot Surgical's $7.85m round led by ZIG Ventures. The data was compiled by market intelligence platform Tracxn, covering exit and funding activity in Singapore's startup ecosystem.PR NewswireBIOBOT SUCCESSFULLY CLOSES S$24 MM SERIES B FUNDING ROUNDBIOBOT Surgical successfully closed a S$24 million Series B funding round led by investor Mr. Tony Tan, with participation from ZIG Ventures and new strategic investors. The company has deployed over 50 Mona Lisa robots globally, completing more than 20,000 procedures, and recently received FDA clearance for its Mona Lisa 2.0 system. The raised capital will be used to fuel global expansion efforts and further develop the company's digital surgery infrastructure.PR Newswire APACCuriox Biosystems Achieves Commercialisation and Fund Raising Success in North Asia with the Support of Cornerstone Investor, ZIG VenturesCuriox Biosystems raised US$15M from Korean investors, with ZIG Ventures as a cornerstone investor. The funds will accelerate global commercialisation, and the company plans an IPO on KOSDAQ within 36 months.PR NewswireCuriox Biosystems Achieves Commercialisation and Fund Raising Success in North Asia with the Support of Cornerstone Investor, ZIG VenturesCuriox Biosystems secured a US$15 million Series B funding round from Korean biotech investors, supported by cornerstone investor ZIG Ventures. The capital will be used to scale up global commercialization activities for its bioinstrumentation solutions, including recent product launches like the Laminar Wash AUTO 1000 and MINI systems. Curiox plans to pursue an Initial Public Offering on the Korean stock exchange within the next 36 months.